170 related articles for article (PubMed ID: 35568771)
21. Immune gene expression profiling reveals heterogeneity in luminal breast tumors.
Zhu B; Tse LA; Wang D; Koka H; Zhang T; Abubakar M; Lee P; Wang F; Wu C; Tsang KH; Chan WC; Law SH; Li M; Li W; Wu S; Liu Z; Huang B; Zhang H; Tang E; Kan Z; Lee S; Park YH; Nam SJ; Wang M; Sun X; Jones K; Zhu B; Hutchinson A; Hicks B; Prokunina-Olsson L; Shi J; Garcia-Closas M; Chanock S; Yang XR
Breast Cancer Res; 2019 Dec; 21(1):147. PubMed ID: 31856876
[TBL] [Abstract][Full Text] [Related]
22. NRF1 motif sequence-enriched genes involved in ER/PR -ve HER2 +ve breast cancer signaling pathways.
Ramos J; Das J; Felty Q; Yoo C; Poppiti R; Murrell D; Foster PJ; Roy D
Breast Cancer Res Treat; 2018 Nov; 172(2):469-485. PubMed ID: 30128822
[TBL] [Abstract][Full Text] [Related]
23. Classification of Osteosarcoma Based on Immunogenomic Profiling.
Wang X; Wang L; Xu W; Wang X; Ke D; Lin J; Lin W; Bai X
Front Cell Dev Biol; 2021; 9():696878. PubMed ID: 34336848
[TBL] [Abstract][Full Text] [Related]
24. PD-L1 expression and CD8-positive T cells are associated with favorable survival in HER2-positive invasive breast cancer.
Hou Y; Nitta H; Wei L; Banks PM; Lustberg M; Wesolowski R; Ramaswamy B; Parwani AV; Li Z
Breast J; 2018 Nov; 24(6):911-919. PubMed ID: 30230111
[TBL] [Abstract][Full Text] [Related]
25. Classification of Muscle-Invasive Bladder Cancer Based on Immunogenomic Profiling.
Zhou X; Qiu S; Nie L; Jin D; Jin K; Zheng X; Yang L; Wei Q
Front Oncol; 2020; 10():1429. PubMed ID: 32974156
[TBL] [Abstract][Full Text] [Related]
26. Association of Depressed Anti-HER2 T-Helper Type 1 Response With Recurrence in Patients With Completely Treated HER2-Positive Breast Cancer: Role for Immune Monitoring.
Datta J; Fracol M; McMillan MT; Berk E; Xu S; Goodman N; Lewis DA; DeMichele A; Czerniecki BJ
JAMA Oncol; 2016 Feb; 2(2):242-6. PubMed ID: 26719971
[TBL] [Abstract][Full Text] [Related]
27. Identification of key differentially expressed genes between ER-positive/HER2-negative breast cancer and ER-negative/HER2-negative breast cancer using integrated bioinformatics analysis.
Gan S; Dai H; Li R; Liu W; Ye R; Ha Y; Di X; Hu W; Zhang Z; Sun Y
Gland Surg; 2020 Jun; 9(3):661-675. PubMed ID: 32775256
[TBL] [Abstract][Full Text] [Related]
28. Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ERα- breast cancer.
Liu JC; Voisin V; Bader GD; Deng T; Pusztai L; Symmans WF; Esteva FJ; Egan SE; Zacksenhaus E
Proc Natl Acad Sci U S A; 2012 Apr; 109(15):5832-7. PubMed ID: 22460789
[TBL] [Abstract][Full Text] [Related]
29. Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules.
Teschendorff AE; Gomez S; Arenas A; El-Ashry D; Schmidt M; Gehrmann M; Caldas C
BMC Cancer; 2010 Nov; 10():604. PubMed ID: 21050467
[TBL] [Abstract][Full Text] [Related]
30. Elevated tumor mutation burden and immunogenic activity in patients with hormone receptor-negative or human epidermal growth factor receptor 2-positive breast cancer.
Xu J; Bao H; Wu X; Wang X; Shao YW; Sun T
Oncol Lett; 2019 Jul; 18(1):449-455. PubMed ID: 31289516
[TBL] [Abstract][Full Text] [Related]
31. Targeting hydrogen sulphide signaling in breast cancer.
Youness RA; Gad AZ; Sanber K; Ahn YJ; Lee GJ; Khallaf E; Hafez HM; Motaal AA; Ahmed N; Gad MZ
J Adv Res; 2021 Jan; 27():177-190. PubMed ID: 33318876
[TBL] [Abstract][Full Text] [Related]
32. A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229).
Chia S; Bedard PL; Hilton J; Amir E; Gelmon K; Goodwin R; Villa D; Cabanero M; Tu D; Tsao M; Seymour L
Oncologist; 2019 Nov; 24(11):1439-1445. PubMed ID: 31420468
[TBL] [Abstract][Full Text] [Related]
33. Ferroptosis regulators, especially SQLE, play an important role in prognosis, progression and immune environment of breast cancer.
Tang W; Xu F; Zhao M; Zhang S
BMC Cancer; 2021 Oct; 21(1):1160. PubMed ID: 34715817
[TBL] [Abstract][Full Text] [Related]
34. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
[TBL] [Abstract][Full Text] [Related]
35. A Tumor initiating cell-enriched prognostic signature for HER2+:ERα- breast cancer; rationale, new features, controversies and future directions.
Liu JC; Egan SE; Zacksenhaus E
Oncotarget; 2013 Aug; 4(8):1317-28. PubMed ID: 23945331
[TBL] [Abstract][Full Text] [Related]
36. Analysis of Lung Adenocarcinoma Subtypes Based on Immune Signatures Identifies Clinical Implications for Cancer Therapy.
Xu F; Chen JX; Yang XB; Hong XB; Li ZX; Lin L; Chen YS
Mol Ther Oncolytics; 2020 Jun; 17():241-249. PubMed ID: 32346613
[TBL] [Abstract][Full Text] [Related]
37. Immune landscape of advanced gastric cancer tumor microenvironment identifies immunotherapeutic relevant gene signature.
Zhang S; Lv M; Cheng Y; Wang S; Li C; Qu X
BMC Cancer; 2021 Dec; 21(1):1324. PubMed ID: 34893046
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+ and FOXP3+ immune cells in HER2-positive breast cancer treated with neoadjuvant therapies.
Zhao J; Meisel J; Guo Y; Nahta R; Hsieh KL; Peng L; Wei Z; O'Regan R; Li X
Breast Cancer Res Treat; 2020 Oct; 183(3):599-606. PubMed ID: 32715443
[TBL] [Abstract][Full Text] [Related]
39. Immune characterization of breast cancer metastases: prognostic implications.
Dieci MV; Tsvetkova V; Orvieto E; Piacentini F; Ficarra G; Griguolo G; Miglietta F; Giarratano T; Omarini C; Bonaguro S; Cappellesso R; Aliberti C; Vernaci G; Giorgi CA; Faggioni G; Tasca G; Conte P; Guarneri V
Breast Cancer Res; 2018 Jun; 20(1):62. PubMed ID: 29929548
[TBL] [Abstract][Full Text] [Related]
40. AR pathway activity correlates with AR expression in a HER2-dependent manner and serves as a better prognostic factor in breast cancer.
Liu D
Cell Oncol (Dordr); 2020 Apr; 43(2):321-333. PubMed ID: 31933152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
